Clinical Trials
AbbVie Secures Approval for EPKINLY in Combination With R2 as the First Bispecific Therapy for Relapsed or Refractory Follicular Lymphoma
EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available f...
November 19, 2025 | News
Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease
Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...
November 18, 2025 | News
Thermo Fisher Scientific Enrolls First Patient in New CorEvitas™ Myasthenia Gravis Real-World Evidence Registry
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&tra...
November 18, 2025 | News
Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan
Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), mark...
November 17, 2025 | News
PRISM BioLab Reaches Initial Milestone in Joint Oncology Research under Agreement with Ono Pharmaceutical
PRISM BioLab, Co. Ltd. ("PRISM") announces that , PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafte...
November 17, 2025 | News
SAS Launches Clinical Acceleration to Modernise Clinical Trial Analytics and Speed Regulatory Submissions
Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new therapies to patients faster&nb...
November 17, 2025 | News
Lupin Launches Risperidone Long Acting Injectable in the United States with PrecisionSphere Technology
Global pharma major Lupin announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 5...
November 17, 2025 | News
Sanyou Bio and Yugong Bio Forge Strategic Alliance to Advance High-End Synthetic Molecular Enzymes
Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step ...
November 12, 2025 | News
Leucid Bio Reports Proof-of-Concept for LEU011 CAR-T Therapy in Solid Tumours from Ongoing AERIAL Trial
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control obser...
November 11, 2025 | News
Simcere Advances Treg-Selective IL-2 Mutant SIM0278 into Phase II Trial for Moderate-to-Severe Atopic Dermatitis
Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278,...
November 11, 2025 | News
Muna Therapeutics Doses First Subjects in Phase 1 Trial of TREM2 Agonist MNA-001 for Alzheimer’s Disease
MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce neurotoxic amyloid burden and reprogram microgl...
November 11, 2025 | News
Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer
Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...
November 11, 2025 | News
Takeda’s Mezagitamab Shows Sustained Kidney Function and Proteinuria Reduction Through 18-Month Follow-Up in IgA Nephropathy
Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 ...
November 10, 2025 | News
PolyActiva and RareSight Forge Strategic Partnership to Develop Sustained-Release Therapies for Rare Pediatric Retinal Diseases
Partnership Leverages PolyActiva’s PREZIA™ Drug Delivery Platform Technology and RareSight’s Expertise in Rare Diseases to Advance Nove...
November 07, 2025 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
